Wolverine Peptide (Wolverine Stack): What It Is, What the Research Shows, and How to Evaluate a Blend
Research use only. Peptides supplied by Peptryn are sold strictly for in vitro and preclinical laboratory research. They are not approved by the FDA for human or veterinary use, and nothing here is medical advice, a dosing recommendation, or an instruction for self-administration. This guide explains what the Wolverine peptide is, what published research does and does not show, and how researchers should evaluate a blend.
Quick answer: what is the Wolverine peptide?
The Wolverine peptide, also called the Wolverine stack, Wolverine peptide stack, or Wolverine blend, is an informal nickname for a combination of two synthetic peptides: BPC-157 and TB-500. The name comes from the comic-book character known for rapid healing, and it reflects how the blend is marketed rather than any proven effect.
The evidence, in short: nearly all supporting data comes from cell and rodent studies. According to a 2025 review, published human data for BPC-157 amounts to three small studies with no randomized trial. Two randomized trials are now registered, and neither has posted results. We found no published controlled human trial of the BPC-157 plus TB-500 combination. Neither compound is an FDA-approved drug.
At a glance
| What it is | A nickname for a blend of BPC-157 and TB-500 (some clinics and sellers add other peptides, so the term is not standardized) |
| Origin of the name | Marketing, after the Marvel character |
| Best evidence | Rodent and cell studies; three small human reports on BPC-157 alone |
| Approved drug? | No |
| Sport status | BPC-157 is prohibited by WADA (S0); TB-500 falls under the WADA S2 class |
| Peptryn’s Wolverine | Lyophilized research blend, 10 mg and 20 mg vials, ≥99% purity by HPLC and mass spectrometry, batch COA. See the product page → |
Researchers sourcing the blend or its components: Wolverine blend · BPC-157 · TB-500 · Batch COA library
Table of contents
- What the Wolverine peptide is (and isn’t)
- The two components: BPC-157 and TB-500
- Why the two are combined
- What the research shows
- Regulatory and sport status
- Safety: what is known and unknown
- Wolverine peptide dosage: why there is no established one
- Wolverine vs Klow vs BPC-157 or TB-500 alone
- How to evaluate a blend before you buy
- FAQ
What the Wolverine peptide is (and isn’t)
There is no single, standardized “Wolverine peptide.” The label describes a blend concept, and the exact contents depend on who is selling it.
- The common definition is BPC-157 plus TB-500. This is what most explainers, including the ones currently ranking on Google, describe.
- Some clinics use a broader recipe. One clinic page in the search results defines its “Wolverine stack” as four peptides: BPC-157, TB-500, CJC-1295, and ipamorelin.
- It isn’t a drug. It has no regulatory identity, no approved dose, and no standard formulation.
That variability is the first practical lesson for anyone evaluating a product sold as “Wolverine”: the name tells you almost nothing about what is in the vial. The certificate of analysis does.
The two components: BPC-157 and TB-500
| BPC-157 | TB-500 | |
|---|---|---|
| Full name | Body Protection Compound-157 | Usually described as a synthetic form of thymosin beta-4 |
| Structure | 15 amino acids (pentadecapeptide): Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Depends on the seller, see below |
| Approximate molecular weight | 1,419.53 Da | 4,963.44 Da (full-length form) or under 1 kDa (7-amino-acid fragment) |
| Origin | Derived from a protein found in human gastric juice; described by Sikiric and colleagues in 1993 | Thymosin beta-4 is a 43-amino-acid protein found in nearly all human cells |
| Half-life | Under 30 minutes in animal work, though effects reported in models last far longer | Not well characterized in humans |
The “TB-500” naming problem
“TB-500” is used for two different molecules, and buyers are rarely told which one they are getting:
- The 7-amino-acid fragment, Ac-LKKTETQ, which copies the actin-binding region (residues 17–23) of thymosin beta-4. This is the form in the one registered human trial of the fragment that we found (see below) and the form the FDA lists as “thymosin beta-4, fragment (LKKTETQ).”
- Full-length thymosin beta-4, the 43-amino-acid protein. Peptryn’s standalone TB-500 listing is this form: 4,963.44 Da, CAS 77591-33-4.
These are not interchangeable. Results, safety findings, and regulatory statements about one do not automatically apply to the other. When you evaluate any blend, check the certificate of analysis for which form is present and confirm the identity by mass spectrometry.
Why the two are combined
The rationale comes from proposed mechanisms in preclinical work, and it is a hypothesis, not a demonstrated result:
- BPC-157 has been reported in rodent studies to activate VEGFR2 and nitric oxide signaling (the Akt-eNOS pathway), which is linked to new blood vessel growth. It has also been reported to support fibroblast activity and collagen synthesis in tendon and ligament models.
- Thymosin beta-4 binds actin and has been studied for its role in cell migration and tissue remodeling.
The argument for stacking them is that they act on different parts of the repair process. That is a reasonable research question. It has not been answered by controlled studies in people, and we found no published controlled human trial that tests the two together.
What the research actually shows
The most useful way to read this literature is by evidence level. Here is what exists as of September 2026.
| Claim or use | Best available evidence | Evidence level |
|---|---|---|
| BPC-157 speeds tendon and ligament healing | Multiple rodent studies reporting faster healing, more collagen, and better tendon-to-bone integration | Preclinical (animal) |
| BPC-157 supports muscle recovery | Rodent injury models reporting improved regeneration and less fibrosis | Preclinical (animal) |
| BPC-157 improves knee pain | Retrospective review of 16 patients; 14 (87.5%) reported significant relief after injections that included BPC-157. No control group (Lee & Padgett, 2021) | Small human report |
| BPC-157 for interstitial cystitis | Pilot study of 12 participants (Lee et al., 2024) | Small human report |
| BPC-157 short-term safety | Two healthy adults given intravenous infusions up to 20 mg with no adverse events reported (Lee & Burgess, 2025) | Very small human report |
| Any BPC-157 randomized controlled trial | None published, according to a 2025 narrative review. Two randomized trials are now registered (NCT07437547 in acute hamstring strain, recruiting; NCT07803250 after rotator cuff repair, not yet recruiting), and neither has posted results | None |
| TB-500 fragment in humans | The FDA has stated it has not identified human exposure data for the fragment. A Phase 1/2 randomized, placebo-controlled safety trial (NCT07487363) began in February 2026 in adults with stable atherosclerotic cardiovascular disease; it targets 80 participants and lists primary completion for February 2027 | Trial underway; not musculoskeletal |
| Full-length thymosin beta-4 in humans | Studied in human trials as pharmaceutical products: topical thymosin beta-4 for venous stasis ulcers (Phase 2, 72 participants, NCT00832091), RGN-259 eye drops for dry eye (Phase 3, 700 participants, NCT03937882), and intravenous recombinant thymosin beta-4 in healthy volunteers (Phase 1a, 54 participants, NCT04555824) and after heart attack (Phase 2, 90 participants, NCT05984134). We did not assess whether these trials succeeded. Each is a different product and route from an injectable research peptide, and these are investigational products | Different molecule |
| “Before and after” transformations | Anecdotes and social media posts | Not evidence |
Three points stand out:
- The animal data is real but limited in what it can tell you. Rodent healing models are not human tendon injuries, and a result in one species frequently fails to translate.
- The human data is thin. The three BPC-157 human reports involve 16, 12, and 2 people. The authors of the 2025 review concluded that BPC-157 should be treated as investigational and not recommended for clinical use in musculoskeletal medicine until well-designed trials exist (McGuire et al., Current Reviews in Musculoskeletal Medicine, 2025).
- The first registered trial of the TB-500 fragment is about safety in cardiovascular disease. It does not test tendon or muscle healing. Its primary outcomes are adverse events (ClinicalTrials.gov, NCT07487363).
Regulatory and sport status
FDA. Neither BPC-157 nor TB-500 is an FDA-approved drug. The FDA has published safety concerns about compounded versions of both, citing possible immunogenicity (an immune response to the peptide, tied to aggregation), peptide-related impurities, and no or limited human safety information. For the TB-500 fragment, the agency states it has identified no human exposure data. As of our September 2026 check, the FDA’s page on bulk drug substances that may present significant safety risks lists both among nominations that were later withdrawn (FDA).
The July 2026 advisory panel. On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding BPC-157 (nominated for ulcerative colitis) and TB-500 (nominated for wound healing) to the list of substances pharmacies may compound. KPV received the same vote. These votes are advisory. They do not make either peptide an approved drug, the FDA is not bound by them, and trade coverage reports that a formal rulemaking process of roughly eight to twelve months would have to follow before pharmacies could compound them. FDA staff recommended against the nominations, citing safety and efficacy concerns, and the committee was described as nearly evenly divided on BPC-157 (Pharmaceutical Executive; RAPS). Regulatory pages and proposals change, so verify the current status before relying on it.
Sport. BPC-157 is prohibited at all times under the S0 (non-approved substances) category of the WADA Prohibited List. The US Anti-Doping Agency states it is unknown whether any dose is safe and that performance claims for BPC-157 lack support in medical literature (USADA). TB-500 is a thymosin beta-4 derivative and is addressed under the S2 class of the WADA Prohibited List. Athletes subject to testing should treat the entire stack as prohibited.
Sale as research material. Peptryn supplies its peptides for laboratory research only, to buyers who are 21 or older and who confirm they are qualified researchers. It is not a compounding pharmacy and does not offer these products for human use.
Safety: what is known and unknown
What the published human reports say. Across the three BPC-157 human reports, no adverse events were reported. That is encouraging, but the combined sample is 30 people, the studies were small pilots or a retrospective review, and the safety pilot had only two participants. It cannot establish safety.
What is theoretical. Reviewers have raised the concern that a compound that promotes blood vessel growth could, in principle, support unwanted vessel growth in tumors, and that heavy nitric oxide signaling could have downstream effects. These are proposed risks, not observed ones, and they cannot be ruled out without proper studies.
What is unknown.
- Long-term safety of either compound
- Safe or effective dose in any human condition
- Interactions with other drugs
- Effects of the combination
What is a practical risk today. Independent of the peptides themselves, the FDA points to aggregation and peptide-related impurities as drivers of immune reactions. Product quality therefore matters as much as the molecule. This is why batch-level testing (purity, identity, endotoxin) is the single most useful thing a researcher can verify.
Wolverine peptide dosage: why there is no established one
“Wolverine peptide dosage” is one of the most-searched phrases in this topic (about 1,300 searches a month, up sharply year over year), and it is worth being direct about what the evidence supports.
There is no evidence-based dose for the Wolverine stack. No controlled human trial has tested the combination. For BPC-157 alone, the largest human study we found gave up to 20 mg intravenously to two healthy adults, which tested tolerability and not effectiveness. USADA states that it is unknown whether there is a safe dose of BPC-157 for any condition. Any dosing chart you see online is extrapolated from animal studies, vendor material, or anecdote.
For that reason this guide does not give doses, schedules, or “cycle” lengths.
What researchers working with the lyophilized powder do need is concentration math, which is independent of any biological question:
Concentration (mg/mL) = peptide mass (mg) ÷ diluent volume (mL)
Peptryn’s reconstitution basics guide, the peptide calculator, and the bacteriostatic water guide cover sterile handling and the arithmetic. Per the product specification, store the lyophilized powder at −20 °C, protected from light and repeated freeze-thaw cycles (storage and handling guide).
Wolverine vs Klow vs BPC-157 or TB-500 alone
Researchers often ask whether to use a blend or individual compounds. Peptryn lists all of them, so here is a factual comparison based on the listings.
| Wolverine | Klow80 | BPC-157 | TB-500 | |
|---|---|---|---|---|
| Type | Blend | Four-component blend | Single peptide | Single peptide |
| Contents | Typically BPC-157 + TB-500 (confirm on the COA) | TB-500 10 mg + BPC-157 10 mg + GHK-Cu 50 mg + KPV 10 mg (80 mg total) | BPC-157 (15 amino acids, 1,419.53 Da) | Full-length thymosin beta-4 (43 amino acids, 4,963.44 Da) |
| Sizes | 10 mg, 20 mg | 80 mg | 5 mg, 10 mg | 10 mg |
| From | $200 | $160 | $79.99 | $89.99 |
| Best for | Studies of the two-peptide combination in one vial | Studies of a multi-pathway combination that adds collagen-related and anti-inflammatory peptides | Isolating BPC-157 effects | Isolating thymosin beta-4 effects |
How to choose. If your protocol needs to attribute an effect to one compound, use single-peptide vials, because a blend cannot separate them. If your protocol specifically tests a combination in a fixed ratio, a blend saves handling steps and reduces the number of vial punctures. Either way, choose based on what your study design needs, not on a marketing name.
Shop the Wolverine blend → · Klow80 → · BPC-157 → · TB-500 → · All research blends →
How to evaluate a blend before you buy
Because “Wolverine” is a nickname, the paperwork is what separates a reliable product from a mislabeled one. Use this checklist.
- A certificate of analysis for your specific lot. It should list the lot number and date, not a generic sample.
- Identity by mass spectrometry for each component. For a two-peptide blend, the COA should confirm both. Purity alone does not tell you what the molecule is.
- HPLC purity, ideally per component. Look for ≥99% on each peptide, not just a combined figure.
- Endotoxin testing. Relevant for any material handled in solution.
- An independent lab. Peptryn’s batch testing is done by MZ Biolabs, and certificates are published by lot in the COA library.
- A clear statement of composition and amount. You should know the milligrams of each peptide per vial.
- The TB-500 form. Ask whether it is the 7-amino-acid fragment or full-length thymosin beta-4 (see above).
- No medical claims from the seller. A supplier that promises healing or performance results for a research chemical is signaling the wrong thing.
- Proper storage instructions and shipping practices. Lyophilized powder should be stored cold and protected from light.
New to reading these documents? Peptryn’s guide on how to read a certificate of analysis walks through each line, and the lab results page shows published reports. If a lot’s certificate isn’t published yet, email support with your order number and they’ll send the current report on file.
Orders ship from the USA with same-day dispatch, and orders over $150 ship free.
Get the Wolverine blend with a batch COA →
Frequently asked questions
What is the Wolverine peptide?
It is a nickname for a blend of BPC-157 and TB-500, two synthetic peptides studied in animal models for tissue repair. The name is marketing, and the blend has no approved use or standard formulation.
What is the Wolverine stack peptide?
“Stack” is a common term in the peptide community for combining more than one compound. The Wolverine stack usually means BPC-157 plus TB-500, though some clinics add other peptides.
What are the Wolverine peptide benefits?
The benefits claimed online include faster recovery, tendon and joint healing, and reduced inflammation. In the research literature those effects are reported in animal models of injury, not established in people. Claimed benefits should be read as hypotheses that controlled human trials have not yet tested.
Does the Wolverine peptide work?
There is no controlled human evidence that it does. Animal studies of BPC-157 and thymosin beta-4 report tissue-repair effects. For BPC-157 those results have not been confirmed in published human trials, and two randomized trials are registered without results. Full-length thymosin beta-4 has been tested in human trials as pharmaceutical products (see the evidence table), and we did not assess their outcomes. The combination has not been tested in controlled human studies.
Does the Wolverine peptide build muscle mass?
No evidence shows that it does. Rodent studies of BPC-157 examine muscle regeneration after injury, which is a different question from muscle growth.
Is the Wolverine peptide safe?
Safety has not been established. Three small BPC-157 human reports (16, 12, and 2 participants) reported no adverse events, but that is too little data to conclude anything. The FDA has published concerns about immunogenicity and impurities for compounded versions of both peptides.
What are the Wolverine peptide side effects?
No reliable side-effect profile exists for the combination. Theoretical concerns include effects tied to blood vessel growth and nitric oxide signaling. Injection-site and immune reactions are also possible with any injected peptide product, particularly if impurities are present.
Is the Wolverine peptide FDA-approved?
No. Neither BPC-157 nor TB-500 is an approved drug, and the FDA has raised safety concerns about compounded versions. In July 2026 an FDA advisory panel voted 8-6 to recommend adding both to the pharmacy compounding list. That is an advisory recommendation about compounding, not an approval, and the FDA is not bound by it.
Is the Wolverine peptide legal?
Peptides are sold in the US as research chemicals for laboratory use. They are not approved for human use, and they are banned in tested sports. If you have legal questions about your situation, consult a qualified attorney.
How long can you take the Wolverine peptide?
No one knows. There is no established duration, dose, or schedule, because no controlled human trial has tested the combination.
What is the difference between Wolverine and Klow?
Wolverine is typically a two-peptide blend (BPC-157 and TB-500). Klow80 is a four-component blend that adds GHK-Cu and KPV to TB-500 and BPC-157. See the comparison table.
Wolverine peptide for sale: where can researchers source it?
Peptryn supplies a Wolverine research blend in 10 mg and 20 mg vials with batch-specific certificates of analysis. View the product → Buyers must be 21 or older and confirm laboratory research use.
Final take
The Wolverine peptide is best understood as a marketing name for a hypothesis: that BPC-157 and TB-500 might support tissue repair through complementary mechanisms. The animal research behind each compound is genuine, the human evidence is very limited, and the combination has not been tested in controlled human studies. For researchers, the practical questions are not about hype. They are about identity, purity, and documentation.
Browse research-grade Wolverine, BPC-157, and TB-500 with batch COAs →
Related guides: BPC-157 research guide · How to read a certificate of analysis · Reconstitution basics for laboratory peptides · Proper storage and handling of research peptides · Where to buy retatrutide: what to verify before you order · Klow peptide guide · MOTS-c peptide guide · SS-31 peptide guide · Glow peptide guide · What is a COA? · Peptide purity · Peptide testing · Popular peptides
Editorial note: Peptryn sells the research peptides discussed in this guide for laboratory use only. This guide is informational and is not medical advice. Sources are listed below. To report an error, email [email protected].
Sources
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine, 2025. pmc.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov
- U.S. Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes. usada.org
- World Anti-Doping Agency. Prohibited List. wada-ama.org
- ClinicalTrials.gov. Phase 1/2 study of TB-500 (thymosin beta 4 17-23 fragment) in adults with stable atherosclerotic cardiovascular disease (NCT07487363; sponsor Hudson Biotech). clinicaltrials.gov
- ClinicalTrials.gov. RGN-259 ophthalmic solution for neurotrophic keratopathy (SEER-1, NCT02600429). clinicaltrials.gov
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- Pharmaceutical Executive. FDA Panel Votes to Loosen Restrictions for Four Peptides. pharmexec.com
- Regulatory Affairs Professionals Society. FDA advisory committee backs two controversial peptides. raps.org
Related: Peptides for muscle growth and recovery: the research
All products on peptryn.com are intended for laboratory research purposes only. Not for human consumption, self-administration, or veterinary use. The information on this page has not been evaluated by the U.S. Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease. Nothing here should be construed as medical advice.
